Regional cerebral blood flow and metabolic changes associated with brain dysfunction induced by antihistamines

Regional cerebral blood flow and metabolic changes associated with brain dysfunction induced by antihistamines - Cerebral blood flow and metabolic changes associated with antihistamines

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016883

Enrollment

Registered

2015-03-23

Start date

2015-03-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy (Healthy volunteers)

Interventions

levocetirizine 5mg diphenhydramine 50mg placebo

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Healthy volunteers (men; young subgroup ranging 20-25 years old) who understand the purpose of this study well. 2) Healthy volunteers with his/her own will and without any subordinate relation. 3) Subjects who can take enough sleep and rest during the night before the clinical test. 4) Subjects who can contact by mobile phones and who can participate 3 serial clinical tests.

Exclusion criteria

Exclusion criteria: Subjects with the following conditions are to be excluded: 1) Subjects who take medication acting on histaminergic nervous systems including antihistamines 2) Subjects with past history of severe epilepsy and allergic reactions 3) Subjects with past history of frequent hospitalization. 4) Subjects with moderate to severe glaucoma and uninary tract obstruction such as prostatic enlargement 5) Subjects with other disorders to which administration of anticholinergic and antihistaminergic treatment is not suitable 6) Subjects with moderate to severe abnormality in renal and liver functions 7) Subjects with moderate to severe cognitive impairment 8) Subjects with abnormality in brain MRI images. 9) other abnormalities, the investigators think the inclusion to this study is not suitable

Design outcomes

Primary

Measure	Time frame
regional cerebral blood flow and metabolism in cognitive tests done after oral administration of levocetirizine 5 mg and diphenhydramine 50mg and placebo.	—

Secondary

Measure	Time frame
subjective sleepiness and performance in cognitive tests done after oral administration of levocetirizine 5 mg and diphenhydramine 50mg and placebo.	—

Countries

Japan

Contacts

Public ContactManabu TASHIRO

Tohoku University Cyclotron and Radioisotope Center Division of Cyclotron Nulclear Medicine (a branch clinic of Tohoku University Hospital)

mtashiro@m.tohoku.ac.jp022-795-7797

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026